Tags

Type your tag names separated by a space and hit enter

Transporter-mediated drug-drug interactions.
Pharmacogenomics. 2011 Jul; 12(7):1017-37.P

Abstract

Drug-drug interactions are a serious clinical issue. An important mechanism underlying drug-drug interactions is induction or inhibition of drug transporters that mediate the cellular uptake and efflux of xenobiotics. Especially drug transporters of the small intestine, liver and kidney are major determinants of the pharmacokinetic profile of drugs. Transporter-mediated drug-drug interactions in these three organs can considerably influence the pharmacokinetics and clinical effects of drugs. In this article, we focus on probe drugs lacking significant metabolism to highlight mechanisms of interactions of selected intestinal, hepatic and renal drug transporters (e.g., organic anion transporting polypeptide [OATP] 1A2, OATP2B1, OATP1B1, OATP1B3, P-gp, organic anion transporter [OAT] 1, OAT3, breast cancer resistance protein [BCRP], organic cation transporter [OCT] 2 and multidrug and toxin extrusion protein [MATE] 1). Genotype-dependent drug-drug interactions are also discussed.

Authors+Show Affiliations

Institute of Experimental & Clinical Pharmacology & Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21787191

Citation

Müller, Fabian, and Martin F. Fromm. "Transporter-mediated Drug-drug Interactions." Pharmacogenomics, vol. 12, no. 7, 2011, pp. 1017-37.
Müller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics. 2011;12(7):1017-37.
Müller, F., & Fromm, M. F. (2011). Transporter-mediated drug-drug interactions. Pharmacogenomics, 12(7), 1017-37. https://doi.org/10.2217/pgs.11.44
Müller F, Fromm MF. Transporter-mediated Drug-drug Interactions. Pharmacogenomics. 2011;12(7):1017-37. PubMed PMID: 21787191.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Transporter-mediated drug-drug interactions. AU - Müller,Fabian, AU - Fromm,Martin F, PY - 2011/7/27/entrez PY - 2011/7/27/pubmed PY - 2011/12/13/medline SP - 1017 EP - 37 JF - Pharmacogenomics JO - Pharmacogenomics VL - 12 IS - 7 N2 - Drug-drug interactions are a serious clinical issue. An important mechanism underlying drug-drug interactions is induction or inhibition of drug transporters that mediate the cellular uptake and efflux of xenobiotics. Especially drug transporters of the small intestine, liver and kidney are major determinants of the pharmacokinetic profile of drugs. Transporter-mediated drug-drug interactions in these three organs can considerably influence the pharmacokinetics and clinical effects of drugs. In this article, we focus on probe drugs lacking significant metabolism to highlight mechanisms of interactions of selected intestinal, hepatic and renal drug transporters (e.g., organic anion transporting polypeptide [OATP] 1A2, OATP2B1, OATP1B1, OATP1B3, P-gp, organic anion transporter [OAT] 1, OAT3, breast cancer resistance protein [BCRP], organic cation transporter [OCT] 2 and multidrug and toxin extrusion protein [MATE] 1). Genotype-dependent drug-drug interactions are also discussed. SN - 1744-8042 UR - https://www.unboundmedicine.com/medline/citation/21787191/Transporter_mediated_drug_drug_interactions_ L2 - http://www.futuremedicine.com/doi/full/10.2217/pgs.11.44?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -